Mouth-nose inhalation administration experimental animal fixer and administration system thereof

Abstract

The utility model relates to the field of experimental animal fixing instruments, in particular to a mouth-nose inhalation administration experimental animal fixing device and an administration system thereof, and particularly relates to an experimental animal fixing device used for being combined with an administration device. An experimental animal fixing device is used for being communicated with a medicine supply device so as to detect the characteristics of experimental medicine through an experimental animal and comprises a shell, the shell comprises a conical part with a conical cavity and a cylindrical part with a cylindrical cavity, and the conical cavity and the cylindrical cavity form a containing cavity for containing the experimental animal; the size of the end, away from the cylindrical part, of the conical part is smaller than that of the end, close to the cylindrical part, of the cylindrical part, and a communicating hole communicating with a medicine supply device is formed in the end, away from the cylindrical part, of the conical part; the propelling unit is adjustably arranged in the cylindrical cavity so as to adjust the space of the accommodating cavity; the adsorption cabin is arranged at the position, corresponding to the expiration part of the experimental animal, of the shell, and the containing cavity achieves gas exchange with the outside through the adsorption cabin.

Description

Technical Field

[0001] The utility model relates to the field of experimental animal fixing equipment, in particular to an oral and nasal inhalation drug administration experimental animal fixing device and a drug administration system thereof, and in particular to an oral and nasal inhalation drug administration experimental animal fixing device used in conjunction with a drug supply device. Background Art

[0002] With the increasing efforts in drug research and development at home and abroad, atomized inhalation therapy is being explored and excavated more and more. Inhalation preparations are no longer limited to the treatment of traditional respiratory diseases such as asthma and chronic obstructive pulmonary disease. They can also be used to treat cardiovascular diseases (coronary heart disease, angina pectoris, etc.), cerebrovascular diseases (stroke, cerebral infarction, migraine, etc.), endocrine diseases (diabetes, etc.), analgesia, nervous system diseases, etc. Inhalation administration is more attractive as another route of administration besides oral and intravenous administration. Inhalation preparations are portable and have good patient compliance. At the same time, they can not only use their physical targeting and local medication to treat lung diseases; they can also use the large lung absorption surface area and rich vascular network for systemic administration of biomacromolecules and poorly soluble drugs. Compared with intravenous injection, inhalation preparations have less mechanical damage, convenient operation, and better patient compliance; compared with oral preparations, inhalation preparations have higher bioavailability and can act directly on the lungs. Lung inhalation preparations are the first choice for the treatment of respiratory system diseases. In recent years, due to the influence of the environment, the incidence of respiratory system diseases has been increasing. Pulmonary inhalation preparations have a fast onset of action, high bioavailability, and few side effects. They are ideal dosage forms for the treatment of respiratory diseases. Inhalation administration has also received more and more attention and recognition, and has great clinical application value. Considering the onset time and efficacy, inhalation preparations have always been the mainstream treatment for respiratory diseases in the European and American markets.

[0003] Before submitting an IND for an innovative drug, it is necessary to conduct tissue distribution tests, acute toxicity tests, repeated dose toxicity tests, irritation tests, allergy tests, safety pharmacology, pharmacokinetics, pharmacodynamics and other tests on animals, and mice are one of the most commonly used animal species.

[0004] During the above-mentioned experimental process, it is usually necessary to use an experimental animal holder to fix it, and then connect it to the drug supply device to form an animal oral and nasal inhalation exposure system. However, in the existing holder, substances that are not fully inhaled by the animal (potential innovative drugs) are discharged into the experimental space through the vents at the head of the holder or the cavity at the tail. Since such candidate drugs have not passed the safety and efficacy evaluation, they are directly inhaled into the lungs by the operator through the mouth and nose, posing potential health risks to the experimental operators. Although during the experimental operation, the experimenters took measures such as wearing masks, they inevitably passively absorbed various types of aerosol preparations, endangering the safety of the operators. Utility Model Content

[0005] In view of the shortcomings of the prior art, the purpose of the utility model is to provide an oral and nasal inhalation drug administration experimental animal fixator and an oral and nasal inhalation exposure drug administration system, so as to at least improve the operating safety of the operator.

[0006] In order to achieve the above-mentioned purpose, the first aspect of the utility model adopts the following technical solutions:

[0007] An oral and nasal inhalation drug administration experimental animal holder, used to connect to a drug supply device to detect the properties of experimental drugs through experimental animals, characterized by comprising:

[0008] A housing, the housing comprising a conical portion having a conical cavity and a cylindrical portion having a cylindrical cavity, the conical cavity and the cylindrical cavity forming a housing cavity for housing the experimental animal, the dimension of the conical portion at one end away from the cylindrical portion is smaller than the dimension of the cylindrical portion at one end close to the cylindrical portion, and the conical portion at one end away from the cylindrical portion is provided with a communication hole communicating with the drug supply device;

[0009] A propulsion unit, the propulsion unit being adjustably disposed in the cylindrical cavity to adjust the space of the accommodating cavity;

[0010] An adsorption cabin is arranged at a shell position corresponding to the exhalation part of the experimental animal, and the accommodating cavity realizes gas exchange with the outside world through the adsorption cabin.

[0011] Optionally, as an embodiment of the present invention, the oral and nasal inhalation drug administration experimental animal holder also includes a feces collection chamber for collecting feces of the experimental animal, wherein

[0012] The length of the conical portion is not greater than the distance from the head of the experimental animal to the excretion portion, the adsorption chamber is arranged below the conical portion, and the feces collection chamber is arranged below the columnar portion.

[0013] Optionally, as an embodiment of the utility model, the oral and nasal inhalation drug administration experimental animal holder further comprises an animal state detection unit for detecting the state of the animal, the animal state detection unit comprises an electrocardiogram detector and an alarm, the alarm is arranged in the accommodating chamber for real-time detection of whether the oxygen and / or carbon dioxide concentration is within a set range, the electrocardiogram detector is used to monitor the electrocardiogram state of the experimental animal through a sensor fixed on the experimental animal, wherein

[0014] The electrocardiograph is arranged below the conical portion and does not interfere with the adsorption chamber, or is arranged below the feces absorption chamber.

[0015] Optionally, as an implementation of the present invention, a vent hole is provided on the conical portion for selectively achieving air exchange between the accommodating cavity and the external environment.

[0016] Optionally, as an implementation mode of the present invention, a one-way perspective film is affixed to the conical portion, and the columnar portion is made of a transparent material, so as to induce the experimental animal to move toward the conical portion.

[0017] Optionally, as an embodiment of the utility model, the propulsion unit and the shell are combined to form an activity space for the experimental animal, and the propulsion unit includes a sealing part and a limiting part, the sealing part is fixedly connected to the limiting part, the sealing part is used to contact the experimental animal and be sealed with the inner wall of the shell, and the limiting part is used to be movably connected to the shell to adjust the activity space.

[0018] Optionally, as an implementation manner of the present utility model, the limiting portion is bolted to the shell, and the sealing portion is arranged on a side of the limiting portion facing the accommodating cavity.

[0019] Optionally, as an embodiment of the present utility model, the limiting portion is arranged outside the shell portion, the limiting portion is used to selectively abut against the outer wall of the shell, and the sealing portion is arranged in the accommodating cavity and is sealed and connected to the inner wall of the shell.

[0020] The second aspect of the utility model provides an animal oral and nasal inhalation exposure drug administration system, comprising a connected drug supply device and the oral and nasal inhalation drug administration experimental animal holder described in the first aspect of the application, wherein the oral and nasal inhalation drug administration experimental animal holder is used to detect the characteristics of experimental drugs through experimental animals.

[0021] Optionally, as an embodiment of the present invention, the end of the tapered portion away from the cylindrical portion is used to be connected to the drug supply device, and the size of the end of the tapered portion away from the cylindrical portion is smaller than the size of the experimental animal.

[0022] Compared with the prior art, the beneficial effects of the utility model are:

[0023] The oral and nasal inhalation drug administration experimental animal holder provided by the utility model enables the propulsion unit to be sealedly connected to the cylindrical cavity, and the gas in the cavity of the shell is exchanged with the external gas through the exchange cavity, which can at least effectively prevent the candidate drug from being directly discharged into the external environment, thereby endangering the safety of the operator.

[0024] At the same time, by setting up a feces cabin, it is beneficial to quickly collect feces and urine excreted by experimental animals, avoid contamination of the oral and nasal inhalation drug administration experimental animal fixators, and avoid interference with experimental data. It is beneficial to the service life of the entire oral and nasal inhalation exposure system and also provides guarantees for the accuracy of experimental data and laboratory hygiene. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative work.

[0026] Figure 1 The utility model is a schematic diagram of the structure of an animal fixer for oral and nasal inhalation drug administration experiments.

[0027] Description of reference numerals:

[0028] 100, housing; 110, tapered portion; 111, communicating hole; 112, ventilation hole; 120, columnar portion;

[0029] 200, propulsion unit; 210, sealing portion; 220, limiting portion;

[0030] 300, adsorption chamber;

[0031] 400, feces collection chamber;

[0032] 500, animal status detection unit. DETAILED DESCRIPTION

[0033] The technical solutions in the embodiments of the present invention will be described clearly and completely below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by those skilled in the art without creative work are within the scope of protection of the present invention. In addition, it should be understood that the specific implementation methods described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention. In the present invention, unless otherwise stated, the directional words used, such as "upper", "lower", "left", "right", "front", and "back", generally refer to the upper, lower, left, and right of the device in actual use or working state, specifically the drawing direction in the accompanying drawings.

[0034] It should be noted that the description order of the following embodiments is not intended to limit the preferred order of the embodiments of the present utility model. In addition, in the following embodiments, the description of each embodiment has its own emphasis. For parts not described in detail in one embodiment, please refer to the relevant description of other embodiments.

[0035] See also Figure 1The figure shows an experimental animal holder for oral and nasal inhalation drug administration, which is used to fix experimental animals that can detect the drug properties of experimental drugs. The experimental animals are preferably mice. The experimental animal holder for oral and nasal inhalation drug administration includes a shell 100 with a hollow cavity, a propulsion unit 200, an adsorption cabin 300 and a feces collection cabin 400.

[0036] The housing 100 includes a housing cavity for accommodating experimental animals. The housing 100 includes a conical portion 110 (in the figure) arranged at the front end and a cylindrical portion 120 arranged at the rear end, the conical portion 110 forms a conical cavity, the cylindrical portion 120 forms a cylindrical cavity, and the conical cavity and the cylindrical cavity are connected to form an accommodating cavity. In a preferred embodiment, the conical portion 110 and the cylindrical portion 120 are integrally arranged. The diameter of the conical portion 110 on the side close to the cylindrical portion 120 is greater than the diameter of the side away from the cylindrical portion 120. The diameter of the conical portion 110 on the side away from the cylindrical portion 120 is smaller than the size of the experimental animal to limit the movement of the experimental animal. The front end of the conical portion 110 is used to communicate with a drug supply device (not shown in the figure), that is, the end of the conical portion 110 away from the cylindrical portion 120 is provided with a connecting hole 111 connected to the drug supply device, and the connecting hole 111 can limit the movement of the experimental animal to the drug supply device. The drug supply device is preferably an atomization bin, which is used to at least accommodate the atomized experimental drug, or the drug supply device itself can also atomize the experimental drug. The utility model does not limit this, as long as it can provide the atomized experimental drug and communicate with the conical cavity. There are many technologies for drug supply devices in the prior art, and the utility model does not repeat them. The conical portion 110 is detachably sealed and connected to the drug supply device, preferably plug-in. The advantage of plug-in is that it is convenient for operators to operate and replace the oral and nasal inhalation drug administration experimental animal holder in time, thereby improving the efficiency of the experiment.

[0037] The propulsion unit 200 is used for detachably sealingly connecting with the cylindrical cavity. The propulsion unit 200 includes a sealing portion 210 and a limiting portion 220. The sealing portion 210 is arranged in the cylindrical cavity for contacting with the experimental animal and sealingly connecting with the inner wall of the housing 100. The limiting portion 220 is fixedly connected with the sealing portion 210. The limiting portion 220 can selectively adjust the relative position with the cylindrical portion 120, that is, the limiting portion 220 is used for movably connecting with the housing 100 to adjust the activity space, so as to adjust the activity space of the experimental animal in the housing 100.

[0038] In a specific embodiment, the limiting portion 220 is bolted to the cylindrical portion 120, and the sealing portion 210 is fixedly arranged on one side of the limiting portion 220 close to the conical portion 110 and is sealed to the inner wall of the shell 100. By adjusting the threaded connection between the limiting portion 220 and the cylindrical portion 120, the activity space of the experimental animal in the shell 100 is restricted.

[0039] In another replaceable embodiment, the limiting portion 220 is arranged outside the cylindrical portion 120, and the limiting portion 220 is used to selectively abut against the outer wall of the cylindrical portion 120. The sealing portion 210 is arranged inside the cylindrical portion 120 and is sealed and connected to the inner wall of the cylindrical portion 120. The sealing portion 210 is fixedly connected to the limiting portion 220. When it is necessary to adjust the activity space of the experimental animal in the shell 100, the limiting portion 220 is adjusted so that the limiting portion 220 does not contact the outer wall of the cylindrical portion 120, and the sealing portion 210 is moved to a specified position. Then, the limiting portion 220 is adjusted so that the limiting portion 220 abuts against the outer wall of the cylindrical portion 120, thereby fixing the relative position of the limiting portion 220 and the cylindrical portion 120, and then fixing the position of the sealing portion 210 relative to the cylindrical portion 120, thereby completing the restriction of the activity space.

[0040] Please continue reading Figure 1 The adsorption cabin 300 is disposed below the conical portion 110 and is in communication with the conical portion 110. The gas in the housing 100 is exchanged with the external environment through the adsorption cabin 300. The adsorption cabin 300 can at least adsorb the experimental drug in the gas to prevent the experimental drug in the gas in the housing 100 from entering the external environment. Preferably, the adsorption cabin 300 is filled with a multi-layer fiber filter element or activated carbon, or a variety of substances capable of adsorbing the experimental drug are placed on the multi-layer fiber filter element according to the characteristics of the experimental drug to achieve better absorption of the experimental drug.

[0041] It can be understood that the advantage of arranging the adsorption cabin 300 below the conical portion 110 is that, due to the physiological structure of experimental animals, their gas exhalation site is mostly located below the body. By arranging the adsorption cabin 300 below, it is possible to adsorb toxic substances in the gas exhaled by the animals more quickly to avoid releasing them to the outside. At the same time, the gas in the cavity can be exchanged with the external air as quickly as possible, thereby improving the air exchange efficiency and avoiding the death of experimental animals due to lack of oxygen in the cavity inside the shell 100.

[0042] Please continue reading Figure 1 The feces collecting chamber 400 is arranged below the columnar portion 120 and is connected to the columnar portion 120 for receiving the excrement of the experimental animals. The feces collecting chamber 400 is not in contact with the external environment. At least one of shavings, bedding or absorbent paper is arranged in the feces collecting chamber 400 to complete the treatment of animal excrement. A plurality of through holes are arranged on the contact surface between the feces collecting chamber 400 and the columnar portion 120 to facilitate the excrement to fall into the feces collecting chamber 400.

[0043] In a preferred embodiment, the length of the tapered portion 110 ( Figure 1The adsorption chamber 300 is arranged in at least a part of the area below the conical portion 110. The advantage of such arrangement is that it can avoid the influence of animal excrement on the adsorption chamber 300, thereby improving the overall gas exchange and adsorption efficiency of toxic substances.

[0044] In another preferred embodiment, the feces collection chamber 400 is disposed in the entire area below the conical portion 110 to maximize the collection of excrement.

[0045] Therefore, through the oral and nasal inhalation drug administration experimental animal holder provided by the utility model, by making the propulsion unit sealedly connected with the cylindrical cavity and making the gas in the cavity of the shell 100 exchange gas with the external connection through the exchange chamber, it can at least effectively prevent the candidate drug from being directly discharged into the external environment, thereby endangering the safety of the operator.

[0046] At the same time, by setting up a feces cabin, it is beneficial to quickly collect feces and urine excreted by experimental animals, avoid contamination of the oral and nasal inhalation drug administration experimental animal fixators, and avoid interference with experimental data. It is beneficial to the service life of the entire oral and nasal inhalation exposure system and also provides guarantees for the accuracy of experimental data and laboratory hygiene.

[0047] Please continue reading Figure 1 The upper surface of the conical portion 110 is provided with ventilation holes 112, which are used to selectively exchange the gas in the cavity of the housing 100 with the air of the external environment. For example, when the oxygen content in the cavity of the housing 100 is too low, or the carbon dioxide content is too high, opening the ventilation holes 112 can greatly increase the gas exchange efficiency between the housing 100 and the external environment, thereby protecting the lives of experimental animals.

[0048] Please continue reading Figure 1 The oral and nasal inhalation drug administration experimental animal holder also includes an animal state detection unit 500 for detecting the state of the experimental animal in real time.

[0049] The animal state detection unit 500 includes an electrocardiogram detector (not shown in the figure) and an alarm (not shown in the figure). The electrocardiogram detector detects the electrocardiogram changes of the experimental animal in real time through a sensor fixed on the animal's epidermis, so that the operator can understand the animal's state in real time. The alarm is arranged on the inner wall of the housing 100, that is, arranged in the accommodating cavity, and is used to detect the concentration of oxygen and / or carbon dioxide in the cavity in real time. When the concentration of oxygen or carbon dioxide in the cavity of the housing 100 is within a set range, for example, when the oxygen concentration is lower than 12%, the alarm sounds an alarm to remind the staff to increase the air exchange between the cavity and the external environment. There are many technical solutions for the electrocardiogram detector and the alarm in the prior art, and the utility model will not repeat them. The electrocardiogram detector is preferably arranged below the conical portion 110 without interfering with the adsorption cabin 300, and can also be arranged below the feces collection cabin 400. It is preferably arranged below the cylindrical portion 120 and arranged on the same horizontal plane as the adsorption cabin 300 and the feces collection cabin 400.

[0050] Please continue reading Figure 1 The sealing portion 210 is provided with an arc-shaped concave surface on one side facing the cylindrical portion 120 for fitting with the experimental animals. The arc-shaped concave surface is used to minimize the damage to the experimental animals during the process of adjusting the experimental activity space.

[0051] Please continue reading Figure 1 The conical portion 110 is affixed with a one-way perspective film for easy observation by the operator, and the cylindrical portion 120 is made of a transparent material. By affixing a one-way vision film on the conical portion 110, a relatively dark environment can be provided for the experimental animals, reducing the fear of the experimental animals for unfamiliar environments. At the same time, the conical portion 110 with the one-way vision film and the cylindrical portion 120 made of a transparent material can induce the experimental animals to move into the conical cavity, increase the amount of drug inhaled by the experimental animals, and reduce the damage to the experimental animals in the process of restricting the animal's movement space. There are many technical solutions for the one-way perspective film in the prior art, and the utility model will not elaborate on this.

[0052] The utility model also provides an oral and nasal inhalation exposure drug administration system, comprising a connected drug supply device and an oral and nasal inhalation drug administration experimental animal holder, which is used to detect the characteristics of experimental drugs through experimental animals. The oral and nasal inhalation drug administration experimental animal holder comprises a shell 100, a propulsion unit 200 and an adsorption cabin 300. The shell 100 has a accommodating cavity for accommodating the experimental animal. The propulsion unit 200 is detachably sealed and connected to the shell 100. The adsorption cabin 300 is detachably fixedly connected to the shell 100. The accommodating cavity of the shell 100 is connected to the drug supply device and the adsorption cabin 300. The adsorption cabin 300 is used to at least adsorb the experimental drug. The accommodating cavity realizes gas exchange with the outside through the adsorption cabin 300, wherein the adsorption cabin 300 is arranged at the position of the shell 100 corresponding to the exhalation part of the experimental animal.

[0053] The above is a detailed introduction to the scheme of the utility model. Specific examples are used in this article to illustrate the principle and implementation method of the utility model. The description of the above embodiments is only used to help understand the method and core idea of ​​the utility model. At the same time, for general technicians in this field, according to the idea of ​​the utility model, there will be changes in the specific implementation method and application scope. In summary, the content of this specification should not be understood as a limitation on the utility model.

[0054] References throughout the specification to "one embodiment," "an embodiment," or "a specific embodiment" mean that a particular feature, structure, or characteristic described in conjunction with the embodiment is included in at least one embodiment of the present invention, and not necessarily in all embodiments. Thus, various appearances of the phrases "in one embodiment," "in an embodiment," or "in a specific embodiment" in different places throughout the specification do not necessarily refer to the same embodiment. In addition, the particular features, structures, or characteristics of any specific embodiment of the present invention may be combined with one or more other embodiments in any suitable manner. It should be understood that other variations and modifications of the embodiments of the present invention described and illustrated herein may be based on the teachings herein and will be considered part of the spirit and scope of the present invention.

[0055] It should also be understood that one or more of the elements shown in the figures may also be implemented in a more separate or more integrated manner, or even removed because they are inoperable in certain circumstances or provided because they may be useful depending on the application.

[0056] In addition, unless otherwise explicitly indicated, any marking arrows in the drawings should be regarded as exemplary only and not limiting. In addition, unless otherwise indicated, the term "or" used herein is generally intended to mean "and / or". In the case where the term is not clear because it is anticipated that the ability to separate or combine is provided, the combination of components or steps will also be regarded as indicated.

Claims

1. An oral and nasal inhalation drug administration experimental animal holder, used to connect to a drug supply device to test the properties of experimental drugs through experimental animals, characterized in that: include: A housing, the housing comprising a conical portion having a conical cavity and a cylindrical portion having a cylindrical cavity, the conical cavity and the cylindrical cavity forming a housing cavity for housing the experimental animal, the dimension of the conical portion at one end away from the cylindrical portion is smaller than the dimension of the cylindrical portion at one end close to the cylindrical portion, and the conical portion at one end away from the cylindrical portion is provided with a communication hole communicating with the drug supply device; A propulsion unit, the propulsion unit being adjustably disposed in the cylindrical cavity to adjust the space of the accommodating cavity; An adsorption cabin is arranged at a shell position corresponding to the exhalation part of the experimental animal, and the accommodating cavity realizes gas exchange with the outside world through the adsorption cabin.

2. The oral and nasal inhalation drug administration experimental animal holder according to claim 1, characterized in that: The oral and nasal inhalation drug administration experimental animal holder also includes a feces collection chamber for collecting feces of the experimental animal, wherein The length of the conical portion is not greater than the distance from the head of the experimental animal to the excretion portion, the adsorption chamber is arranged below the conical portion, and the feces collection chamber is arranged below the columnar portion.

3. The oral and nasal inhalation drug administration experimental animal holder according to claim 2, characterized in that: The oral and nasal inhalation drug administration experimental animal holder also includes an animal state detection unit for detecting the state of the animal, and the animal state detection unit includes an electrocardiogram detector and an alarm. The alarm is arranged in the accommodating cavity and is used to detect in real time whether the oxygen and / or carbon dioxide concentration is within a set range. The electrocardiogram detector is used to monitor the electrocardiogram state of the experimental animal through a sensor fixed on the experimental animal, wherein The electrocardiograph is arranged below the conical portion and does not interfere with the adsorption chamber, or is arranged below the feces absorption chamber.

4. The oral and nasal inhalation drug administration experimental animal holder according to claim 2, characterized in that: The conical portion is provided with a vent hole for selectively achieving air exchange between the accommodating cavity and the external environment.

5. The oral and nasal inhalation drug administration experimental animal holder according to claim 2, characterized in that: The conical part is affixed with a one-way perspective film, and the columnar part is made of a transparent material, which is used to induce the experimental animal to move toward the conical part.

6. The oral and nasal inhalation drug administration experimental animal holder according to any one of claims 1 to 5, characterized in that: The propulsion unit and the shell are combined to form an activity space for the experimental animal. The propulsion unit includes a sealing portion and a limiting portion. The sealing portion is fixedly connected to the limiting portion. The sealing portion is used to contact the experimental animal and be sealed with the inner wall of the shell. The limiting portion is used to be movably connected to the shell to adjust the activity space.

7. The oral and nasal inhalation drug administration experimental animal holder according to claim 6, characterized in that: The limiting portion is connected to the housing bolts, and the sealing portion is arranged on a side of the limiting portion facing the accommodating cavity.

8. The oral and nasal inhalation drug administration experimental animal holder according to claim 6, characterized in that: The limiting portion is arranged outside the shell portion, and is used to selectively abut against the outer wall of the shell. The sealing portion is arranged in the accommodating cavity and is sealed and connected with the inner wall of the shell.

9. An oral and nasal inhalation exposure drug delivery system, characterized in that: It comprises a connected drug supply device and an oronasal inhalation drug administration experimental animal holder as described in any one of claims 1 to 8, wherein the oronasal inhalation drug administration experimental animal holder is used to detect the characteristics of experimental drugs through experimental animals.

10. The oral and nasal inhalation exposure drug delivery system according to claim 9, characterized in that: The end of the tapered portion away from the columnar portion is used to communicate with the drug supply device, and the size of the end of the tapered portion away from the columnar portion is smaller than the size of the experimental animal.

Images